Aveo Pharmaceuticals Inc. buy stratec
Startpreis
21.10.18
/
50%
22,28 €
Kursziel
02.07.19
37,88 €
Rendite (%)
-72,32 %
Endpreis
02.07.19
6,17 €
Zusammenfassung
Diese Einschätzung wurde am 02.07.19 mit einem Endkurs von 6,17 € beendet. Herbe Verluste von -72,32 % verzeichnete die BUY Einschätzung von stratec. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Aveo Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -0,68 % | 1,89 % | 15,37 % | 17,16 % |
| iShares Nasdaq 100 | 0,33 % | 4,63 % | 29,82 % | 56,19 % |
| iShares Nikkei 225® | -1,49 % | -2,36 % | 7,67 % | 3,63 % |
| iShares S&P 500 | -0,52 % | 2,32 % | 25,46 % | 46,45 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Aveo Pharmaceuticals diskutieren
Being optimistic about AVEO's mid- and long-term potential.
AVEO has a number of shots on deck relating to tivozanib, with possible other catalysts emerging from its nascent drug programs in development. In late 2018 and into 2019, here are some of the items
we can expect:
- Top line data from TIVO-3, which will inform the likelihood of getting approval for tivozanib in the US.
- Submission of a new drug application to the FDA for tivozanib.
- Updated
data from the expansion phase of TiNivo, giving a better sense of the
feasibility and efficacy of the tivozanib-nivolumab combination. - Updates on the development of ficlatuzumab, an HGF scavenger being studied in several solid tumors.
- Initiation of a phase 1 trial for CAN017, a HER3 antibody being developed in partnership with CANbridge Life Sciences in China.
(Vom Mitglied beendet)